A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack
Acute Ischaemic Stroke, Transient ischaemic attack
40 Years - 130 Years
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Dec 2020 by AstraZeneca
No locations available
Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
|Placebo Comparator: TICAGRELOR PLACEBO|
Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.